Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study

<b>Background:</b> Both pemafibrate and sodium glucose cotransporter-2 (SGLT2) inhibitor can decrease serum transaminase levels in patients with non-alcoholic fatty liver disease (NAFLD) complicated with dyslipidemia and type 2 diabetes mellitus (T2DM), respectively. However, the effecti...

Full description

Bibliographic Details
Main Authors: Satoshi Shinozaki, Toshiyuki Tahara, Kouichi Miura, Alan Kawarai Lefor, Hironori Yamamoto
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Life
Subjects:
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
pemafibrate
dyslipidemias
PPAR-alpha
sodium glucose transporter-2 inhibitors
Online Access:https://www.mdpi.com/2075-1729/13/6/1327

Internet

https://www.mdpi.com/2075-1729/13/6/1327

Similar Items